+

WO1996040250A3 - Platelet-specific chimeric immunoglobulin and methods of use therefor - Google Patents

Platelet-specific chimeric immunoglobulin and methods of use therefor Download PDF

Info

Publication number
WO1996040250A3
WO1996040250A3 PCT/US1996/010216 US9610216W WO9640250A3 WO 1996040250 A3 WO1996040250 A3 WO 1996040250A3 US 9610216 W US9610216 W US 9610216W WO 9640250 A3 WO9640250 A3 WO 9640250A3
Authority
WO
WIPO (PCT)
Prior art keywords
platelet
specific chimeric
immunoglobulin
methods
chimeric immunoglobulin
Prior art date
Application number
PCT/US1996/010216
Other languages
French (fr)
Other versions
WO1996040250A2 (en
Inventor
Barry S Coller
David M Knight
Original Assignee
Centocor Inc
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc, Univ New York State Res Found filed Critical Centocor Inc
Priority to AU63323/96A priority Critical patent/AU6332396A/en
Priority to JP9502244A priority patent/JPH11511120A/en
Priority to EP96922452A priority patent/EP0835135A2/en
Publication of WO1996040250A2 publication Critical patent/WO1996040250A2/en
Publication of WO1996040250A3 publication Critical patent/WO1996040250A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Agents which selectively bind GPIIb/IIIa and the vitronectin receptor are disclosed and can be used to reduce or prevent occlusion, reocclusion (e.g, abrupt closure), stenosis and/or restenosis. In one embodiment, an immunoglobulin or immunoglobulin fragment, such as a platelet-specific chimeric immunoglobulin or fragment thereof comprising a nonhuman antigen binding region and a human constant region, is used in the method.
PCT/US1996/010216 1995-06-07 1996-06-05 Platelet-specific chimeric immunoglobulin and methods of use therefor WO1996040250A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU63323/96A AU6332396A (en) 1995-06-07 1996-06-05 Platelet-specific chimeric immunoglobulin and methods of use therefor
JP9502244A JPH11511120A (en) 1995-06-07 1996-06-05 Platelet-specific chimeric immunoglobulins and methods of using the same
EP96922452A EP0835135A2 (en) 1995-06-07 1996-06-05 Platelet-specific chimeric immunoglobulin and methods of use therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47552695A 1995-06-07 1995-06-07
US08/475,526 1995-06-07

Publications (2)

Publication Number Publication Date
WO1996040250A2 WO1996040250A2 (en) 1996-12-19
WO1996040250A3 true WO1996040250A3 (en) 1997-01-23

Family

ID=23887963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/010216 WO1996040250A2 (en) 1995-06-07 1996-06-05 Platelet-specific chimeric immunoglobulin and methods of use therefor

Country Status (7)

Country Link
EP (1) EP0835135A2 (en)
JP (1) JPH11511120A (en)
CN (1) CN1186439A (en)
AU (1) AU6332396A (en)
CA (1) CA2223885A1 (en)
NZ (1) NZ513882A (en)
WO (1) WO1996040250A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
ES2257094T3 (en) * 1998-11-03 2006-07-16 Centocor, Inc. MODIFIED ANTIBODIES AND ANTIBODY FRAGMENTS WITH INCREASED DURATION OF ACTIVITY.
AUPP783198A0 (en) * 1998-12-21 1999-01-21 Resmed Limited Determination of mask fitting pressure and correct mask fit
WO2000066160A1 (en) * 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
EP1719529A4 (en) * 2004-02-25 2008-05-21 Astellas Pharma Inc Contrast medium for thrombus formation
EP2789631A1 (en) * 2013-04-10 2014-10-15 Synapse B.V. Compounds and methods for inhibition of binding of ICAM-4 to platelet integrin alphaIIbbeta3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012734A1 (en) * 1991-01-17 1992-08-06 The Board Of Regents Of The University Of Washington Anti-growth factor antibodies in the treatment of vascular stenosis
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
WO1995012412A1 (en) * 1993-11-05 1995-05-11 Centocor, Inc. Platelet-specific chimeric immunoglobulin and methods of use therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
WO1992012734A1 (en) * 1991-01-17 1992-08-06 The Board Of Regents Of The University Of Washington Anti-growth factor antibodies in the treatment of vascular stenosis
WO1995012412A1 (en) * 1993-11-05 1995-05-11 Centocor, Inc. Platelet-specific chimeric immunoglobulin and methods of use therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARRY S. COLLER ET AL.: "New Antiplatelet Agents: Platelet GPIIb/IIIa Antagonists", THROMBOSIS AND HAEMOSTASIS, vol. 74, no. 1, - July 1995 (1995-07-01), pages 302 - 308, XP002019167 *
WILLIAM E. ROTE ET AL.: "Prevention of Rethrombosis After Coronary Thrombolysis in a Chronic Canine Model. I. Adjunctive Therapy with Monoclonal Antibody 7E3 F(ab')2 Fragment", J. CARDIOVASCULAR PHARMACOLOGY, vol. 23, no. 2, 1994, pages 194 - 202, XP002019168 *

Also Published As

Publication number Publication date
EP0835135A2 (en) 1998-04-15
JPH11511120A (en) 1999-09-28
AU6332396A (en) 1996-12-30
CN1186439A (en) 1998-07-01
CA2223885A1 (en) 1996-12-19
NZ513882A (en) 2001-09-28
WO1996040250A2 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
EP1266965A3 (en) Recombinant antibodies for human therapy
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
NZ596723A (en) Human antibodies that bind human il-12 and methods for producing
ZA93779B (en) Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5.
ES2106195T3 (en) IGG AGLYCOSILATED ANTIBODY ANTI CD3.
EP1378525A3 (en) Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods
AU1241795A (en) Anti-egf-r/anti-cd3 bispecific monoclonal antibody, method for its production and its use
ZA949341B (en) Humanized antibodies and uses thereof
GEP20105118B (en) Anti-vegf antibodies
AU3327701A (en) Humanized anti-ccr2 antibodies and methods of use therefor
WO1998018826A3 (en) Anti-CCR5 antibodies and methods of use therefor
WO1994019466A3 (en) A novel family of anti-carcinoembryonic antigen chimeric antibodies
WO2000005265A3 (en) Anti-crr2 antibodies and methods of use therefor
CA2429027A1 (en) Antibodies against human receptor h4-1bb
WO1999003987A3 (en) Syncytial respiratory virus epitopes and antibodies comprising them, useful in diagnosis and therapy
AU7198291A (en) Human monoclonal antibodies against rabies viruses, the production and the use thereof
WO1996040250A3 (en) Platelet-specific chimeric immunoglobulin and methods of use therefor
EP1176201A3 (en) Platelet-specific chimeric immunoglobulin
AU4748893A (en) Reshaped monocolonal antibodies against an immunoglobulin isotype
EP0396505A3 (en) Monoclonal antibodies specific for an immunoglobulin isotype
CA2126182A1 (en) Humanized antibodies reactive with gpiib/iiia
AU2547995A (en) Monoclonal antibody specific for vascular endothelial cell antigen endoglyx-1, the antigen itself, and uses thereof
AU3923293A (en) Human monoclonal antibodies and methods for human monoclonal antibody production
IN172885B (en)
EP1334730A3 (en) Platelet-specific chimeric immunoglobulin and methods of use therefor

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96194312.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996922452

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 311914

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 1997 502244

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2223885

Country of ref document: CA

Ref document number: 2223885

Country of ref document: CA

Kind code of ref document: A

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996922452

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996922452

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载